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.:1 Cv~i?pmlofkb (CyA)-based immunosuppression 
slgmficantly enhanced both patient and graft survival 
in all solid organ transplants. when compared to the era of 
azathioprine and steroids. The widespread use ofCyA has 
spawned a growing body of experience delineating the side 
effects of Cy A use. which was apparent in the first reports 
on human patients.' Prior to the utilization of monitoring 
techniques. renal dysfunction was often used as a guideline 
to effective Cy A dosing.2 More recently, monitoring of 
CyA trough levels has been used to guide eyA dosing,J 
although some patients manifest toxicity at "therapeutic 
levels." while others do not manifest any side effects at 
levels considered "excessive".· This has held true. 
regardless of the development of a number of different 
assay systems monitoring either parent Cy A drug or its 
metabolites. 
Nephrotoxicity remains the principle limiting side effect 
of Cy A, and has been reported to occur in more than 50% 
of patients. Unfortunately. the mechanism(s) of eyA 
nephrotoxicity have not been clearly defined. Hyperten-
sion (40% to 60%), hyperkalemia, hirsutism (60% to 80%), 
gingival hypertrophy, hepatotoxicity (40% to 60%), and 
tremors are relatively common side effects of CyA (re-
viewed by Thiru'). 
Malignant complications include a higher incidence of 
posttransplant lymphoproliferative disease (PTLD). as 
well as a variety of skin cancers, including Kaposi's 
sarcoma. PTLD is an abnormality of lymphocyte prolifer-
ation in a setting of an immunosuppressed patient. The 
spectrum of PTLD can range from a benign lymphoid 
proliferation. such as a mononucleosis syndrome. to a 
frankly malignant lymphoid tumor. PTLD has been asso-
ciated with all types of immunosuppressive therapy. The 
incidence of PTLD in the Cy A era is generally estimated 
between 2% and 4%. 7 Most (90% to 95%) of PTLD are B 
cell in origin. and most are associated with integration of 
Epstein-Barr virus (EBV) DNA into the genome of the B 
cell. A smaller number of PTLD are T cell in origin. 
Because of the relatively high percentages of patients 
developing rejection on eyA therapy (estimated at 50% to 
70%), multiple drug combinations have been utilized to 
prevent rejection. while minimizing toxicities. The se-
quelae of overimmunosuppression in attempts to treat 
rejection. such as use of excessive steroids. antilympho-
cyte preparations, are fraught with a high incidence of 
infectious complications and metabolic sequelae. such as 
diabetogenesis and ulcerogenesis. In addition. each com-
ponent of the "cocktail", has its inherent limitations. It 
stands to reason that a baseline immunosuppressive agent 
which allows for less incidence of rejection. and easier 
treatment of rejection. would decrease both graft and 
patient loss. 
FK 506 is a recent addition to the armamentarium of 
immunosuppressive agents. FK 506 shares some pharma-
cologic similarities with eyA, such as bioavailability, 
lipophilicity, and hepatic metabolism.8 Both drugs bind to 
proteins having a peptidyl·prolyl cis·trans isomerase activ-
ity, although the binding proteins for eyA and FK S06 are 
unique.9 A wealth of animal datal()"12 and human experi· 
ence13- 16 suggest that FK 506 is effective in both the 
prevention and treatment of rejection. FK S06 appears to 
not only decrease the absolute incidence of rejection 
episodes, and allows for marked reduction in steroid 
doses. but makes the treatment of rejection much simpler. 
Nevertheless. a delineation of the side effects of FK 506 
therapy is important in the comparison of two effective 
immunosuppressive agents. FK 506 and eyA share some 
of the same side effects. although they differ significantly in 
other important aspects. The purpose of this study was to 
examine the adverse effects associated with FK S06 ther-
apy. 
Adverse reactions requiring treatment or adjustment of 
FK S06 doses can be categorized into four primary areas: 
(1) alterations in kidney function: (2) alterations in glucose 
metabolism: (3) neurotoxicity; and (4) susceptibility to 
infection or malignancy. 
STUDY SOURCES 
Since the introduction of FK 506 to clinical trials in 
February 1989. and December 31. 1990, a total of 1057 
patients have been enrolled. for both primary therapy and 
rescue therapy. The vast majority of patients studied have 
been patients who have received liver transplants. There· 
fore. most of the data regarding the toxicity of FK S06 
were compiled from a series of 370 consecutive primary 
liver transplant patients transplanted between August 1989 
and December 1990. A smaller series of 41 patients were 
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randomized to receive FK 506 in a trial comparing FK 506 
and eyA in low-risk liver transplant patients. 17 Reference 
to 208 kidney transplant recipients 18 and 52 heart trans-
plant patients19 will also be made. 
In the group of 370 primary liver transplant patients. the 
median follow-up was 377 days. Fifty-four patients died 
(mortality was 14.6%). The I-year patient survival was 
86%. No deaths were directly attributed to FK 506 ther-
apy. 
In the randomized study, a total of 41 patients received 
FK 506. The median follow-up was 343 days. The overall 
mortality in the FK 506 limb was 7%. and the I-year 
patient survival was 93%. 
NEPHROTOXICITY 
Alterations in kidney function are manifested by electro-
lyte abnormalities and changes in glomerular filtration. as 
evidenced by changes in serum creatinine. Significant 
hyperkalemia. following administration of FK 506. was 
defined as a serum potassium greater than 5.1 mEq/L. 
which required treatment. Treatment of hyperkalemia was 
generally with potassium-binding resins or potassium-re-
stricted diets. Because many of these patients have a 
relative hyporenin-hypoaldosterone status, addition of a 
synthetic mineralocorticoid, Florinef. relieves the hyper-
kalemia by increasing potassium excretion by the kidney. 
Approximately 50% of liver transplant patients on FK 506 
require treatment for hyperkalemia. The incidence in other 
organ transplant systems is less: for heart transplant recip-
ients. Florinef is utilized in less than 20% of patients. 
Decrements in renal blood flow following liver trans-
plantation has been documented by nuclear medicine 
studies. The filtration fraction generally remains the same. 
Causes of altered renal function in transplant patients are 
multifactorial and include: perioperative hypotension. se-
verely altered hepatic function. use of nephrotoxic antibi-
otics. degree of preexisting renal dysfunction. and high 
levels of FK 506. In fact, liver transplant patients have 
been shown to have a mean decrease in estimated renal 
blood flow of 32% prior to transplantation.::o 
In the liver transplant patients. renal dysfunction was 
classified as "acute" if elevation of serum creatinine (SCr) 
to >3.0 mgldL occurred within the first 30 days following 
transplantation in patients whose pretransplant SCr was 
:s2.0 mgldL. Excluding 21 patients who were on hemodi-
alysis prior to liver transplantation and an additional S 
patients with SCr >2.0 mgldL. the overall incidence of 
renal dysfunction in the first month was 36.2% (134 pa-
tients). A careful analysis of "contributing factors" (use of 
nephrotoxic antibiotics. primary nonfunction of the liver. 
and the requirement for retransplantation) revealed that 64 
of the 134 patients had one or more of these complicating 
factors. The mortality of the contnbuting factor group was 
29 of 64 (45%). verifying the impact of these factors on 
patient surviVal. Pure FK 506 nephrotoxicity was found in 
the other 70 patients. and only. ol)e patient died in this 
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group. The peak SCr was similar in both groups (4.34 ± 
1.46 mgldL for the FK S06 toxicity 4.59 ± 1.29 mgldL for 
the contributing factors). Of significance was the difference 
in the FK 506 level at the time of the peak SCr. In the FK 
506 toxicity group. the FK 506 level was 4.06 :t 3.1 .. 
ng/mL. occurring a median of 6 days following transplan-
tation. In the other group. the FK 506 level was 7.03 ± 
10.47 nglmL at 5 days posttransplantation. A total of SI 
(23.2%) patients required hemodialysis following trans-
plantation (does not include the 21 patients on hemodial-
ysis prior to transplantation). Only 30 of the 81 patients 
were in the FK 506 toxicity group, while the rest were in 
the contributing factor group. Improvement of renal func-
tion was the rule (94%) in both groups if the patients 
survived. although recovery took twice as long (16 days) in 
the contributing factors group when compared to the FK 
506 toxicity group (S.5 days). 
Chronic nephrotoxicity was defined as a SCr >2.0 
mgldL occurring after the first 30 days following transplan-
tation. In the series of 370 patients. a total of 115 patients 
(31.1%) with a SCr :s2.0 mgldL prior to transplantation. 
had a rise to over this value after 30 days. Forty of these 
115 patients recovered a SCr :s2.0 mgldL following 
changes in FK 506 dosing, requiring a mean of 154 days to 
accomplish this. 
In the 41 patients who were in the randomized group, 
hemodialysis was required in 4 patients (10%) during the 
posttransplant period. Long-term hemodialysis was re-
quired in one patient (3%). The mean SCr was determined 
during various intervals following transplant. The SCr at 1. 
2.3.4. and 6 months following transplantation were: 1.54. 
1.70. 1.71, 1.61, and 1.75 mgldL. respectively. In this 
study, the incidence of nephrotoxicity was somewhat less 
than that for the CyA group. Thirty-three percent of the 
randomized FK 506 patients in the randomized trial had a 
SCR >2.0 mgldL at 6 months posttransplant. The progres-
sion of chronic renal failure to dialysis requiring renal 
failure is not known. 
No patient has required maintenance hemodialysis fol-
lowing heart transplantation. Renal dysfunction in this 
group of patients was manifested by a peak SCr of 2.25 
mgldL within the first 30 days posttransplant. Chronic 
nephrotoxicity appeared to be more prevalent in the heart 
transplant patients. with 60% of patients having an ele-
vated SCr > 2.0 mgldL at 6 months posttransplant. Only 
one non transplant patient, with a diagnosis of T-cell lym-
phoma (Sezary syndrome) required hemodialysis. but in a 
setting of having received high doses of aminoglycosides to 
control recurrent sepsis. 
Hypertension. in previously normotensive patients. may 
be a result of excessive water volume. intrinsic renal 
damage, or increased vasomotor tone. Concomitant usage 
of glucocorticoids or mineralocorticoids may lead to reten-
sion of excessive water. Liver failure patients manifest a 
low peripheral resistance prior to transplant. which may 
mask essential hypertension until the transplant is com-
pleted. The incidence of newly diagnosed cases in the 370 
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primary liver transplant patients was 42.4% (157 patients). 
A total of 38 of these patients were able to be successfully 
taken off of antihypenensive medications. as the fluid 
status of the recipients normalized. The randomized liver 
patients had an incidence of hypenension at 3 and 12 
months of 27% and 33%. respectively. A low incidence of 
hypenension (20%) was also seen in hean transplant 
patients. 
DIABETOGENESIS 
Alterations in glucose metabolism are the result of changes 
in peripheral sensitivity to insulin and/or changes in the 
response of the islet cells to hyperglycemia. Factors which 
affect perioperative glucose metabolism are: high glucose 
administration in hyperalimentation. steroid administra-
tion. and excessive catabolic states such as sepsis. 
The overall incidence of hyperglycemia requiring insulin 
during the posttransplant period was 35.5% (l5l patients 
out of 370 liver transplant recipients). The timing following 
transplantation suggests that perioperatlve events were 
more likely to lead to insulin requirement than the use of 
FK 506, since the median time to initiation of insulin 
therapy was only 2 days. Recovery was noted in 106 of 
these recipients. so that the incidence of long-term insulin 
requirement was 12.1%. 
The incidence of new onset diabetes was approximately 
10% in FK 506 kidney transplant patients. This is the same 
incidence as was seen in the early hean transplant trials 
(10%). The incidence of new-onset diabetes in other im-
munosuppressive regimens. incorporating CyA or azathi-
oprine. is approximately 20%. The long-term consequence 
of insulin requirement in transplant patients toward the 
development of diabetic complications is not known. 
NEUROTOXICITY 
Liver transplant patients are panicularly prone to the 
development of perioperative neurologic events. The sus-
ceptibility of liver transplant patients to changes in serum 
electrolytes has been previously reponed_ For the pur-
poses of this discussion. mild neurotoxicity is manifested 
by insomnia. mild tremors. headaches. photophobia. and 
hyperesthesias. Significant. severe neurotoxicity is defined 
as confusion requiring investigation, new onset of sei-
zures. persistent coma. or dysarthria (expressive aphasia). 
The overall incidence was 8.4% (31 patients). and was 
broken down into: confusion (12 patients). seizures (\0 
patients). dysarthria (5 patients). and persistent coma (4 
patients). 
INFECTIOUS AND MALIGNANT COMPLICATIONS 
A total of 16 patients have developed de novo PTLD 
lesions while on FK 506 therapy, both primary and rescue 
therapy. Seven of these patients died, although PTLD was 
associated with death in only five cases. The remaining 9 
patients had relatively mild forms of ~aI 3 of these had 
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a mononucleosis syndrOme with presentation of sore 
throat and tonsillar enlargement. Treatment with lowering 
immunosuppression and IV acyclovir proved to cure all of 
them. In the remaining 6 patients, 3 required operative 
procedures (2 small bowel resections, I liver resection) 
which were directly related to PTLD, while the other 3 
were treated by reduction of immunosuppression only. 
The incidence of de novo PTLD following initiation of FK 
506 therapy was 1.4%. All of the cases of PTLD occurred 
within the first year following initiation of FK S06. with the 
median time from FK S06 therapy to onset of disease being 
4 months. FK 506 shows no evidence of any increase in the 
risk of developing or succumbing to PTLD when com-
pared to previously quoted figures on the incidence of 
PTLD (based on other immunosuppressive regimens). No 
patients treated with FK S06 for nontransplanted indica-
tions have developed any malignancies. 
Cytomegalovirus (CMV) infections are considered the 
most common opponunistic infection in the transplant 
patient. Several factors determine the severity and devel-
opment of CMV infections. The seronegativity and use of 
intensive immunosuppression are considered major con-
tributing factors. The incidence of CMV infections in the 
FK S06-treated transplant patients is approximately 20%. 
This figure is similar to that seen in transplanted patients 
on Cy A. No patient treated with FK 506 for nontransplant 
indications has developed CMV infection. 
DISCUSSION 
Since both FK 506 and Cy A appear to act, in pan, by 
inhibition of a family of isomerase enzymes, it is reason-
able to expect that some of the side effects are similar. 
However. one of the major benefits of FK 506 appears to 
be a relative lack of some of the side effects of Cy A. Some 
of these are cosmetic. such as hirsutism and gingival 
hyperplasia. which has not been seen with FK 506. Other 
more significant side effects. such as hypenension. appear 
to be less in the FK S06 patients than for those on Cy A. 
Hypenension. which is seen in 60% to 70% of all Cy A-
treated patients. may result in complications such as 
hypenensive stroke. cardiomyopathy. and augment renal 
failure. The incidence of hypenension in FK 506-treated 
patients appears to be at least 50% less. The ability to use 
less steroids in patients with FK 506. when compared to 
Cy A, may result in less complications ascribed to chronic 
steroid use, such as: osteoporosis. Cushinoid habitus. 
stunted growth. ulcerogenesis. and diabetes. 
A clearer profile of adverse reactions and side effects of 
the drug has been accumulated. In humans. the primary 
side effects of FK 506, in order of decreasing frequency, 
are: insomnia. tremors. headaches. tingling sensations. 
muscle achiness. itching, fatigue. visual sensitivity to light. 
and GI symptoms. In a prospective. randomized study, the 
side effects of FK 506 were compared to that of Cy A. The 
only differences between the two drugs were an increased 
incidence of headaches and insomnia in the FK 506 group, 
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while those on Cy A had an increased incidence of hair 
growth. 
The treatment for the four areas of toxicity varies. to a 
large extent. on the degree of toxicity. Generally. toxicity 
improves with lowering the doses of FK 506. Some reac-
tions. such as the development of dysarthrias. may be 
idiosyncratic or require mUltiple factors in order to become 
apparent and. therefore. may not respond to decreased 
doses of FK 506. Specific therapy or supportive measures 
are indicated until the toxicity resolves. The requirement 
for hemodialysis in liver transplant patients is one such 
example. Renal dysfunction in these cases is generally 
reversible. 
While it has taken over 10 years to elucidate the limita-
tion of Cy A therapy, we believe that the profile of adverse 
effects of FK 506 has been determined. Schemes to 
minimize these effects will increase the safety of this agent 
for immunosuppression. 
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